-
Product Insights
NewDry Powder Inhaler Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder. GlobalData's Medical Devices sector report, “Dry Powder Inhaler Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" provides comprehensive information about the Dry Powder Inhaler Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Dry Powder Inhaler Devices report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NTO-1151 in Neuroendocrine Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NTO-1151 in Neuroendocrine Tumors report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NTO-1151 in Neuroendocrine Tumors Drug Details: Triapine (NTO-1151) is under development for...
-
Product Insights
Vaginal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Vaginal Cancer - Drugs In Development, 2023’, provides an overview of the Vaginal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vaginal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Influenza A Virus, H7N9 Subtype Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenza A Virus, H7N9 Subtype Infections - Drugs In Development, 2023’, provides an overview of the Influenza A Virus, H7N9 Subtype Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Avian Influenza – Drugs In Development, 2023
Global Markets Direct’s, ‘Avian Influenza - Drugs In Development, 2023’, provides an overview of the Avian Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development for Avian Influenza, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neuroendocrine Tumors – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Tumors - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Tumors pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neuroendocrine Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Cancer - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Influenzavirus A Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Influenzavirus A Infections - Drugs In Development, 2023’, provides an overview of the Influenzavirus A Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Influenzavirus A Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AU-314 in High-Grade Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AU-314 in High-Grade Glioma Drug Details: AU-314 is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CC-95775 in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CC-95775 in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CC-95775 in Basal Cell Carcinoma (Basal Cell...